Prognostic utility of tumor grade and IDH-mutation status for immunotherapy response in high grade glioma: a systematic review and meta-analysis.

J Clin NeurosciJul 20, 2026 (epub)
Clinical ResearchOncology (Medical)Neurology

Srivats Srinivasan, Mohammad Mirahmadi Eraghi, Peace Odiase et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the prognostic value of tumor grade and IDH-mutation status in high-grade gliomas treated with immunotherapy. It included 21 studies with 207 patients having grade III gliomas and 11 studies with 115 IDH-mutant gliomas. Newly diagnosed IDH-mutant gliomas showed significantly better overall survival (43.13 months) compared to recurrent IDH-mutant gliomas (19.57 months, p=0.005).

Key findings

  • Overall survival for recurrent and newly diagnosed grade III gliomas was not significantly different (21.90 vs 29.71 months, p=0.237).
  • Newly diagnosed IDH-mutant gliomas had significantly lower 5-year mortality compared to recurrent cases (10.26% vs 59.78%, p<0.001).
  • Dendritic cell and peptide vaccines improved overall survival in IDH-mutant gliomas compared to other immunotherapy agents (p=0.002).

Why it matters

Understanding the impact of tumor grade and IDH status on immunotherapy outcomes can guide treatment decisions and patient counseling in high-grade glioma management. This study highlights the need for tailored approaches based on tumor characteristics.

What to keep in mind

The study is limited by the predominance of single-arm studies and small sample sizes, which may confound the results.

Source

PubMed · PMID 42475978

Published in J Clin Neurosci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchPreventive Medicine / Public Health

2025 National Guidelines on the Mediterranean Diet: Executive Summary of a Joint Report by Italian Scientific Societies and the National Institute of Health Task Force on Clinical Practice Guidelines.

This systematic review and practice guideline, developed by a multidisciplinary panel using NUTRIGRADE, assessed Mediterranean diet evidence across nine health domains and one economic domain.

Nutr RevNov 12, 2026Read summary
Clinical ResearchOrthopedic Surgery

Prevention of Venous Thromboembolism after Total Hip or Knee Replacement.

This multicenter randomized comparative-effectiveness noninferiority trial compared 30 days of aspirin, warfarin, or rivaroxaban for VTE prophylaxis after elective total hip or knee arthroplasty.

N Engl J MedNov 12, 2026Read summary
Clinical ResearchAnesthesiology

Effect of discontinuing antihypertensives on perioperative hypotension in older patients before non-cardiac surgery: multicentre, randomised, double blind, controlled trial.

This multicentre, randomised, double blind, placebo controlled trial assessed whether withholding ACE inhibitors or ARBs on the morning of surgery reduces perioperative hypotension in older adults undergoing non-cardiac…

BMJNov 11, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.